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Abstract
Study objective -  To assess the per­
formance of breast cancer screening in 
different age categories over two decades. 
Design -  Important determinants of re­
duced breast cancer mortality such as at­
tendance, mammography performance, 
cancer detection, and disease stage were 
recorded.
Setting -  Nijmegen, The Netherlands, 
1975-92.
Subjects -  Since 1975 more than 40 000 
women aged 35 years and older have been 
invited biennially for breast screening in 
a population based project in Nijmegen. 
Main results -  Rates of attendance, re­
ferral, detection, and disease stage were 
calculated, as well as the specificity of 
screening mammography and the pre­
dictive value of referral and biopsy. From 
round 3 onwards, the attendance rate of 
women younger than 50 years stabilised at 
70%, in women of 50-69 years it was 62%, 
and in women aged 70 and over it was 22%.
«
In these three age categories, the referral 
rates of a positive screening mam­
mography per 1000 screened women were 
4’9, 6*2, and 11*8, respectively. Specificity 
rates were between 99% and 100%. Current 
predictive values of referral were high: in 
the specific age categories 39%, 59%, and 
68% of the referred women had cancer. 
Detection rates remained fairly stable over 
the rounds 4-9, at 1-9, 3*6, and 8*0 cancers 
per 1000 screened women. In the two year 
period between screening the numbers of 
interval cancers per 1000 screened women 
were 2*2, 2*2, and 2*9, for the three age 
categories respectively. With regard to in­
vasive cancers detected during screening, 
the percentage of small tumours (<20 mm  
on the mammogram) was 84% in each 
age category. For women younger than 50 
years, the proportion of intraductal car­
cinoma in all the cancers detected at 
screening was 40%, while it was 15% in the 
other age categories.
Conclusion -  Throughout the nine rounds, 
the screening outcomes were found to be 
adequate, particularly considering the 
high specificity rate and the predictive 
value of referral without the interference 
of a low detection rate. Although the oc­
currence of interval cancers seemed high, 
it was similar to other screening pro­
grammes. Despite a relatively low referral 
rate, the ratios of screen detected versus
interval cancer cases were favourable. 
Well organised screening programmes 
can achieve good mammography results 
without too many false positives. It is 
important that women continue to 
participate in a screening programme be­
cause cancer can still be detected even 
after several successive negative screening 
examinations.
{J Epidemiol Community Health 1996;50:353-358)
The generally accepted conclusion from ran­
domised trials is that regular mammographical 
screening results in a 20-40% reduction in 
breast cancer mortality.1“6 For current and 
newly started programmes, it is important to 
have some idea of the screening outcomes that 
may be expected, As determinants for expected 
reductions in breast cancer mortality in the 
population, rates of attendance and detection 
as well as disease stage need to be assessed. 
Measures such as positive predictive value in 
the case of referral for further diagnostic evalu­
ation specificity rate, and predictive value of 
biopsy, play important roles in community 
health care and economics.
The breast cancer screening programme in 
Nijmegen started in 1975, Women are sent an 
invitation for a screening mammography once 
every two years. Up to the ninth rounds more 
than 40 000 women had been invited. The 
findings of these nine screening rounds are 
presented, stratified into the age categories 
<50, 50-69, and >70 years at each invitation, 
which also enabled us to study age specific 
trends in screening mammography per­
formance.
Methods
THE SCREENING PROGRAMME
The population based programme in the city 
of Nijmegen (145 000 inhabitants) offered nine 
rounds of screening with an interval of two 
years. In the first screening round, conducted 
in 1975-76, all the women bom between 1910 
and 1939 were sent a personal letter inviting 
them to participate. In the subsequent screen­
ing rounds, women born before 1910 were also 
invited. After the fourth round, women born 
between 1940 and 1944 also received an in­
vitation and after the fifth round tiiose born in 
1945 were invited. From round 6 onwards, all 
the women born before 1947 were invited. In 
the ninth round, women aged 70 years and 
older were offered the opportunity to undergo
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Table 1 N um ber o f invited , scree?ted} referred and biopsied women and  num ber o f cancers at screening rounds, biopsy, and  in the interscreening period 
o f two years
1st round 2nd round 3rd round 4th round 5th round 6th mnnd 7th round 8tJi mutid 9th round
All ages
Invited 23 210 30 553 29 004 28 033 29 978 30 596 30 200 28 960 26 435
Screened 19 702 19 787 16 632 15 111 16 170 16 482 16 480 15219 13201
First screening* 19 702 4056 621 387 3054 1477 1380 498 1 0 0
Referred 254 203 127 128 1 1 0 85 98 85 90
Cancer at screeningf 75 (9) 79 (8 ) 53 (9) 47 (8 ) 57 (11) 60 (17) 57 (9) 53 (8 ) 60 (1 0 )
Biapsy 182 142 98 8 8 79 69 77 61 65
Cancer at biopsy 72 74 50 40 54 56 52 40 47
Interval cancerj* 32 (3) 37 (3) 30 (0) 35 (4) 26 (0 ) 34 (3) 43(1) 42 (1) 28 (2 )
Women under 50 y  at screening
Invited 11 1 0 2 9238 7544 6058 8294 7960 7636 5663 3841
Screened 9681 7165 5509 4281 5910 5642 5356 3931 2621
First screening* 9681 466 145 113 2854 1142 1124 234 44
Referred 108 63 34 33 30 19 2 0 2 0 13
Cancer at screening! 21 (5) 1 2  ( 1 ) 8  (2 ) 7 (4 ) 8  (3) 10(5) 8  (4) 11 (3) 8  (2 )
Biopsy 71 42 26 26 2 1 15 17 16 1 2
Cancer at biopsy 2 0 1 2 7 6 8 9 8 1 0 8
Interval cancerj’ 15 (1) 9 (2 ) 1 0  (0 ) 1 2 (1 ) 5(0) 17 (2 ) 8 (0 ) 1 2  (0 ) 6 (0 )
Women aged 50-69 y  at screening^
Invited 12108 14849 14 752 14 808 14 299 14 566 14 319 14 801 14 306
Screened 1 0  0 2 1 10 334 9340 9119 8588 8942 9055 9352 9306
First screening* 1 0 0 2 1 1302 215 195 145 268 2 0 2 223 53
Referred 146 1 0 0 70 65 62 48 54 45 62
Cancer at screening! 54 (4) 44 (6 ) 33 (5) 25 (4) 38 (6 ) 34 (8 ) 32 (2) 28 (4) 40 (7)
Biopsy 1 1 1 71 55 44 46 40 41 31 42
Cancer at biopsy 52 41 32 2 1 36 33 29 2 0 31
Interval cancerf 17 (2) 23 (1) 18 (0 ) 19 (3) 14 (0) U (0 ) 30(1) 2 2 ( 1) 2 1  (2 )
Women aged 70 y  or older at screening
Invited --- 6466 6708 7167 7385 8070 8245 8496 8288
Screened —~ 2288 1783 1711 1672 1898 2069 1936 1274
First screening* --- 2288 261 79 55 67 54 41 3
Referred --- 40 23 30 18 18 24 2 0 15
Cancer at screeningf --- 23 (1) 1 2  (2 ) 15 (0) 11 (2 ) 16 (4) 17 (3) 14 (1) 1 2  (1)
Biopsy --- 29 17 18 1 2 14 19 14 U
Cancer at biopsy --- 2 1 11 13 1 0 14 15 1 0 8
Interval cancerf --- 5 (0) 2  (0 ) 4 (0) 7 (0) 6 (1 ) 5 (0 ) 8  (0 ) 1 (0 )
* Number of women screened for the first time out of die total number of screened women, 
f in  parentheses,, the number of ductal carcinoma in situ out of the total number of cancers, 
J in  the first screening round only women aged 50-65 y.
screenings but had to make an appointment for 
a screening examination themselves.
At the screening centre , single view mam­
mography was carried out in subsequent 
screening rounds. Initially a lateral view and 
from the fourth round onwards a mediolateral- 
oblique view was taken, using a General Elec­
tric (CGR) 600 T. The films were processed 
and first studied by the radiographer. A second 
view was taken in the cranio caudal direction 
of one breast if the quality was not good enough 
for evaluation (for example, because of over­
projection) 3 or of both breasts if a lesion was 
suspected. All the films were read by at least 
one and mostly two radiologists, who decided 
whether referral was necessary. Referral was 
based on characteristics such as density and 
specific microcalcifications or indirect signs 
such as asymmetry of the breast tissue or nipple 
retraction.
The general practitioners of women whose 
mammograms suggested possible malignancy 
were informed of this and advised to refer these 
women to one of the two hospitals in Nijmegen, 
where complete mammography and physical 
examination were conducted. The so called 
“diagnostic mamma-team”, comprising ra­
diologists, surgeons, and pathologists, decided 
whether any further diagnostic tests were 
needed.
The screening outcomes over the first six 
screening rounds (1975-86) presented by birth 
cohort have been published before.7 Data from 
the subsequent three screening rounds (1987- 
92) are now available and add substantially to 
the earlier results.
STATISTICAL METHODS 1
For each round, all the numbers and rates 
were calculated according to age at the specific 
screening invitation. Specificity denotes the 
number of true negative screening results in 
relation to the total number of “non-cancer” 
women. This was calculated as the number of 
negative screening results divided by die total 
number of screened women minus the number 
of patients detected by screening.8
Results
The outcomes of all nine rounds of the screen­
ing programme are presented in table 1. Table 
2 presents the effect measures calculated from 
these outcomes.
ATTENDANCE
In the period 1975-92, a total of 41 087 women 
were screened with 148 699 mammograms. For 
women younger than 50 years the attendance 
(fig 1) remained fairly stable, at about 70%, 
between 1981 and 1992 (rounds 4-9). The 
attendance rate for women aged 50-69 years 
stabilised at slightly more than 60%. For 
women aged 70 and older, the attendance rate 
had declined to below 20% by the ninth round. 
In the ninth round approximately 35% of all 
the women who had been invited at least eight 
times had been screened 8 times (always) j 20% 
had been screened 6-7 times, 20% 4-5 times 
and 25% less than 3 times. Approximately 10% 
of the women who were invited to the ninth 
round had never been screened.
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Table 2 Statistical screening outcomes in three
1st round
All ages
Attendance (%) 84’9
Referral (%) 12-9
Detection Screening (%) 3-8
PV+referral (%) 29-5
PV+biopsy (%) 39*6
Specificity (%) 99-1
Diagnosis Interval (%) 1-6
Screen/(Screen -I- Inter)* (%) 70* 1
Women under 50 y  at screening
Attendance (%) 87-2
Referral (%) 11-2
Detection Screening (%) 2*2
PV + referral (%) 19*4
PV+biopsy(%) 28-2
Specificity (%) 99-1
Diagnosis Interval (%) 1*5
Screen/(Screen + Inter)* (%) 58*3
Women aged 50-69 y  at screeningf
Attendancc(%) 82*8
Referral (%) 14*6
Detection Screening (%) 5*4
PV +referral (%) 37-0
PV + biopsy (%) 46*8
Specificity (%) 99*1
Diagnosis Interval (%) 1*7
Screen/(Screen +Inter)* (%) 76-1
Women aged 70 y  or older at screening 
Attendance (%)
Referral (%)
Detection Screening (%)
PV + Referral (%)
PV +Biopsy (%)
Specificity (%)
Diagnosis Interval (%)
Screen/(Screen + Inter)* (%)
%e groups over the nine screening rounds
2nd mund 3rd round 4th round 5th round
64*8 57*3 53-9 53*9
10*3 7*6 8*5 6 -8
4-0 3*2 3*1 3*5
38-9 41-7 36*7 51*8
52*1 51*0 45*5 68*4
9 9 . 4 99*6 99*5 99*7
1-9 1*8 2*3 1*6
68*1 63*9 57*3 68*7
77-6 73*0 70*7 71*3
8*8 6*2 1-1 5*1
1-7 1-5 1*6 1-4
19*0 23-5 2 1 * 2 26*7
28-6 26*9 23*1 38-1
99*3 99*5 99*4 99-6
1*3 1*8 2*8 0 - 8
57*1 44*4 36*8 61*5
69-6 63*3 61*6 60*1
9*7 7*5 7*1 7*2
4*3 3-5 2*7 4*4
44-0 47-1 38*5 61-3
57-7 58*2 47*7 78-3
99*5 99-6 99*6 99*7
2*2 1*9 2 -1 1-6
65-7 64*7 56*8 73-1
35*4 26*6 23*9 2 2 - 6
17*5 12*9 17*5 10*8
1 0 -1 6*7 8*8 6*6
57*5 52*2 50*0 61*1
72*4 64*7 72*2 83*3
99-2 99*4 99*1 99*6
2*2 1*1 2-3 4*2
82*1 85*7 78-9 61*1
6th mund 7th round 8th mund 9th round
53*9 54*6 52*6 49*9
5-2 5*9 5*6 6 * 8
3*6 3-5 3*5 4*5
70*6 58*2 62*4 66*7
81*2 67-5 65*6 72*3
99-8 99-8 99*8 99-8
2 - 1 2 * 6 2 - 8 2 - 1
63-8 57-0 55*8 6 8 - 2
70*9 70*1 69*4 6 8 * 2
3*4 3*7 5*1 5*0
1 - 8 1*5 2*8 3-1
52-6 40-0 55*0 61*5
60*0 47*1 62*5 66-7
99-8 99*8 99*8 99*8
3-0 1*5 3*1 2*3
37-0 50*0 47*8 57*1
61-4 63*2 63*2 65*0
5*4 6 * 0 4-8 6*7
3*8 3*5 3*0 4*3
70-8 59*3 62*2 64*5
82*5 70*7 64-5 73*8
99*8 99*8 99*8 99*8
1*2 3*3 2*4 2*3
75*6 51*6 56*0 65*6
23*5 25*1 2 2 * 8 15-4
9*5 1 1 - 6 10*3 1 1 * 8
8*4 8 * 2 7*2 9*4
88-9 70*8 70*0 80-0
1 0 0 * 0 78*9 71*4 72*7
99-8 99*7 99*7 99-8
3*2 2*4 4*1 0 - 8
72*7 77*3 63*6 92*3
*Ratio of the number of screen detected v summation of the number of screen detected and interval cancers, 
fin the first screening round only women aged 50-65 y.
PV+ -  predictive value positive.
REFERRAL
For all the age categories, the referral rates 
for further evaluation were highest in the first 
screening round (see table 2). At that initial 
screening the age specific referral rates per 1000 
screened women were 11-2, 14-6, and 17-5 for 
the three groups respectively. During the course 
of the programme, these figures declined to an
100
60
0)oc(O
T3c
40
20
0
Age <50 y
Age 50-69 y
x
■x
x ■x- •X, Age 70+ y
•x.
1 3 4 5 6  7 
Screening round
8
Figure 1 Attendance per 100 women invited (three 
rounds moving average).
average value (rounds 4-9) of 4-9 for women 
younger than 50 years and 6*2 for those aged 
50-69. For the older women3 the referral rate 
stabilised at 11*8 per 1000 screened women.
SPECIFICITY AND PREDICTIVE VALUE
In the first round the overall specificity was 
99-1%, which increased to 99*8% by the sixth 
round and remained stable thereafter.
The positive predictive values (PV-hve) of 
referral (fig 2)5 that is., the number of cancers 
detected among 100 positive screening tests 
(referred women), showed a sharp increase 
after the fourth round. For the women younger 
than 50 years, the PV+ve increased from 20% 
to 62% in the ninth round. For the women 
aged 50-69 years and the women aged 70 years 
and older, the PV+ve increased from about 
37% and 58%, to 65% and 80%, respectively.
About 70% of all the referred women under­
went a biopsy. The positive predictive value of 
biopsy designates the number of cancers among 
the women who had a biopsy. This PV + ve of 
biopsy converged from 40% to 72% in round 
9.
BREAST CANCER
After the third round, detection rates of breast 
cancer (lobular carcinoma in situ excluded) 
remained stable over the rounds for all three 
age groups -  at approximately 1*9, 3-6, and 
8-0 cancers per 1000 women screened (fig 3).
From round 4 onwards, and considering all 
cancers, women younger than 50 years had a 
higher proportion of in situ carcinomas (40%
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Figure 3 Breast cancer detection per 1000 women 
screened ( three w unds m oving average).
(21/52)), than the women in the age groups 
50-69 years and 70 years and older (16% (31/ 
196) and 13% (11/84) respectively).
The percentages of small (<20 mm) 
tumours in invasive cancers detected by screen­
ing were 83*9% (26/31) for the age group 
younger than 50 years, 84-2% (139/165) for 
the middle age groups and 83-8% (62/74) for 
the patients of 70 years and older.
The interval cancer rates in the two year 
period between screening (fig 4) were fairly
stable over rounds 4-9 for the age categories 
younger than 50 and 50-69 years; there were 
2-2 interval cancers per 1000 women screened. 
For women aged 70 years and older, the figures 
increased from 1*7 (rounds 2-3) to 2*9 per 
1000 screened women in rounds 4-9. The 
interval cancer rates in the first year of the two 
year interscreening period were 0*83, 0*52, and 
0-66 respectively per 1000 screened women for 
the three age categories. The ratios of the 
number of cancers detected by screening versus 
the summation of the number of screen de­
tected and interval cancers remained fairly 
stable at 46%, 63%, and 73% (rounds 4-9)5
respectively.
Discussion
Attendance is an important determinant of fu­
ture breast cancer mortality reduction in the 
total community who are offered a screening 
programme. Almost all trials have presented 
their attendance rates according to age at the 
initial invitation. Mostly., the target populations 
comprised a very large age span. As many 
of the participants will reach the oldest age 
category during the course of the screening 
programme, it is not surprising that clear re­
ductions in attendance are observed when data 
are presented according to age at entry.
Most of the newly started programmes go 
beyond the trial sphere and have a target popu­
lation in the age category 50-70 years. Com­
pliance at the initial screening examination in 
Nijmegen was inversely related to age. It was 
high (83%) in the 50-70 year age category. A 
decline in attendance was observed in all age 
groups at the second screening examination. 
Thereafter, the attendance rate stabilised at 
between 60 and 70% for the age categories 
under 50 and 50-69 years. This level of at­
tendance is considered acceptable.9 No special 
effort was undertaken in Nijmegen to maintain 
this attendance rate other than sending a per­
sonal letter of invitation, including one re­
minder if necessary, every two years. For the 
age category 70 years and older, comorbidity, 
impaired functional status, and reduced social 
support influenced attendance. Although the 
low attendance in this oldest age category will 
affect the effectiveness of the screening pro­
gramme at the population level, the group of 
older women who participate can still benefit 
from screening.10
Of particular interest were the women aged 
50-51 years in 1975 at the start of the pro­
gramme, These women had 10 scheduled 
screening sessions ahead of them up to the age 
of 70 years. At the first invitation, compliance 
was 85%), at the second it was 77% with a stable 
rate of 68% thereafter up to and including the 
ninth round.
Another measure that evaluates the efficacy 
of screening is the breast cancer detection rate. 
In the first screening round, a worthwhile de­
tection rate in the screened women needed to 
be a multiple of the expected annual incidence 
rate.9 This expected annual incidence rate was 
not recorded directly but it could be derived 
from the expected rate in the total population
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Figure 4 Two year internal cancer rates per 1000 women  
screened (three rounds moving average),
and the rate in the group who did not attend. 
To calculate the expected incidence, figures 
from the city of Arnhem (a neighbouring city 
without a screening programme) were used.11 
The detection rate at the first screening round 
was almost tiiree times the expected annual 
incidence rate. This ratio expressed a fa­
vourable outcome for the lead time dis­
tribution, which in turn gave an indication of 
the average length of time that the diagnosis 
was advanced by screening. The ratio between 
the first detection rate and the expected in­
cidence rate in Nijmegen was similar to the 
ratio reported in the results of the Swedish 
trials.12
It was remarkable that there was no reduction 
in the detection rates across the nine screening 
rounds. In all die age categories, the breast 
cancer detection rate remained fairly stable and 
only showed an initial decline after the first 
screening round. Obviously, breast cancer 
keeps on developing in women of all ages. No 
reasonable biological explanation can be given 
for the increase in detection in the youngest 
group from round 8 onwards. No new younger 
birth cohorts were invited for screening in 
Nijmegen after the seventh round, and the 
absolute numbers of breast cancer cases were 
fairly small, approximately 10 at each round 
which may be responsible for the increase in 
the detection rate. It is also possible that die 
mammography technique has improved during 
the same period and yielded more mam- 
mographically detectable preclinical cancers, 
including intraductal carcinomas. This pro­
position is refuted, however, by the observation 
of high incidence rates of interval cancers. Even 
after the fourth screening round, for each two 
screen detected cancers, one interval cancer
Table 3 Detection rate and interval cancer rate fo r  the breast cancer demonstration 
project (B C D P ) 3 Sweden , and  Nijmegen
1st round 
detection 
rate (%)
Subsequent 
rounds detection 
rate (%)
1st round, 1st 
year internal 
cancer rate (%)
Subsequent 1st 
year internai 
cancer rate (%)
Women aged 35-49  v at entry
BCDP 3-0 1-9 0 - 6 0 - 8
Nijmegen 2 - 2 1*7 0-4 0*8
Sweden --- --- -- —
Women aged 50-69 y  at entry
BCDP 7-9 3*3 1*0 0-9
Nijmegen 5*6 4-1 0 - 6 0 - 6
Sweden 6 - 8 4-3 1 0-3 0-4
was diagnosed in the interscreening period of 
two yearsj in the women younger than 50 years 
the ratio was even one to one.
The u n aggressive attitude to m ammo graphic 
screening in The Netherlands compared with 
the USA has been criticised. l3~15 The Nijmegen 
radiologists showed far less inclination to refer 
women with non-specific mammographical 
signs for further diagnostic tests. This policy is 
recognisable in the Nijmegen project dirough 
the low referral rates, though low referral was 
not achieved at the cost of die detection 
rate, which was similar to other screening 
programmes.416
Assessment of this issue through reviewing 
published reports (meta-analysis) is handi­
capped by the fact that very few data are avail­
able from screening projects with long term, 
well documented sets of mammograms and 
clinical follow up in the USA. Only die breast 
cancer demonstration project17 mentions 
screen detected and interval cancers. The de­
tection rate during the first year was very high 
(table 317) but declined towards die level seen in 
Nijmegen in the consecutive years. In addition, 
the interval cancer rates were fully comparable 
with the Nijmegen rates in the first year of die 
two years3 interscreening period. Comparison 
of interval cancers as a proportion of underlying 
incidence (incidence in the adjacent population 
of Arnhem) were similar to other studies.1819
A prerequisite for an effective programme is 
a favourable tumour size at presentation. The 
proportion of small tumours in patients in the 
age category 50-69 years was similar to that 
in other studies.42021 The issue of the ductal 
carcinoma in situ (DCIS) must also be raised, 
as this lesion is diagnosed relatively frequently 
in breast cancer screening projects, DCIS con­
stitute about 10-20% of all breast cancers de­
tected in the screened population,22 whereas 
the detection rate is only 3-5% in clinical 
practice. In our series, the relative frequency 
of ductal carcinoma in situ (DCIS) among all 
cancers from the fourth round onwards, was 
approximately 40% in die age category <50 
years, 16% in die 50-69 year old category, and 
13% in the elderly. The absolute detection rates 
of DCIS in the specific age groups in Nijmegen 
during round 7 up to and including 9, the 
current steady state, were 0*75/103 ( = 9/ 
11939), 0-50/103 (=14/27651) and 0-95/103 
( =  5/5258), respectively. This forms a “J” shape 
with the elderly at die top, the 50-69 year 
olds at the bottom, and the younger group 
somewhere in between.
The extent to which the “J” shaped detection 
rate of DCIS across the age groups is (partly) 
caused by clinically non-relevant DCIS in the 
group of women younger than 50 years who 
never develop an invasive tumour is open to 
speculation. Comedo and non-comedo (poorly 
and well differentiated) hi stop atho logical typ­
ing is currently performed on all DCISs to 
provide insight into the padiogenesis of DCIS 
and suitable methods of treatment.2324 Even 
after the latest treatment results published in 
1993,25 it has still not been indisputably re­
solved whether the treatment of choice for 
DCIS or its subtype diagnosed on the basis of
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mammography and histology (whether or not 
displaying multicentricity)* should be mast­
ectomy, lumpectomy plus radiotherapy, or lum­
pectomy alone (that is, wait and see). The 
subject becomes even more urgent in countries 
with recently launched screening programmes 
such as in Sweden3 the UK, and The Neth­
erlands, because it can be expected that they 
will have to deal with DCIS in increasing num­
bers of women. It has been estimated that 
screening will detect 250-300 cases of DCIS 
each year in tire Dutch national screening pro­
gramme.26
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